Verve Therapeutics Inc [NASDAQ: VERV] closed the trading session at $5260000.0 on 2025-06-26. The day’s price range saw the stock hit a low of $11.165, while the highest price level was $11.27.
The stocks have a year to date performance of 113.16 percent and weekly performance of 1.21 percent. The stock has been moved at 96.08 percent over the last six months. The stock has performed 162.35 percent around the most recent 30 days and changed 108.43 percent over the most recent 3-months.
If compared to the average trading volume of 5.26M shares, VERV reached to a volume of 4107848 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Verve Therapeutics Inc [VERV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VERV shares is $12.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VERV stock is a recommendation set at 2.56. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Verve Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on April 15, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on April 08, 2024, representing the official price target for Verve Therapeutics Inc stock. Previously, the target price had yet another raise to $29, while Canaccord Genuity analysts kept a Buy rating on VERV stock.
The Price to Book ratio for the last quarter was 2.11, with the Price to Cash per share for the same quarter was set at 5.58.
VERV stock trade performance evaluation
Verve Therapeutics Inc [VERV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.21. With this latest performance, VERV shares gained by 162.35% in over the last four-week period, additionally plugging by 96.08% over the last 6 months – not to mention a rise of 99.56% in the past year of trading.
Verve Therapeutics Inc [VERV]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Verve Therapeutics Inc [VERV] shares currently have an operating margin of -349.68% and a Gross Margin at 88.53%. Verve Therapeutics Inc’s Net Margin is presently recorded at -303.64%.
Return on Equity for this stock declined to -26.89%, with Return on Assets sitting at -26.89%.
Earnings per share (EPS) analysis for Verve Therapeutics Inc [VERV] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VERV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Verve Therapeutics Inc go to -0.31%.
Verve Therapeutics Inc [VERV]: Institutional Ownership
There are presently around $94.63%, or 99.72% of VERV stock, in the hands of institutional investors. The top three institutional holders of VERV stocks are: ALPHABET INC. with ownership of 12.35 million shares, which is approximately 14.6618%. BLACKROCK INC., holding 6.62 million shares of the stock with an approximate value of $$32.31 million in VERV stocks shares; and BLACKROCK INC., currently with $$25.69 million in VERV stock with ownership which is approximately 6.2492%.
